Immunogenetics of Severe Bacterial Disease Susceptibility and Vaccine Responses...
Immunogenetics of Severe Bacterial Disease Susceptibility and Vaccine Responses in Humans
Defining the genetic basis of differential susceptibility to infectious diseases is of importance for understanding the evolution of human genetic diversity, for identifying critical molecular pathways in disease resistance, and f...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
BAXERNA 2.0
Immunopeptidomics-based Development of Next-Generation Bacte...
9M€
Cerrado
ImmRisk
Defining how environmental factors influence downstream effe...
1M€
Cerrado
GATTACA
Genetics of Alternative Transcript Abundance upon immune Cel...
173K€
Cerrado
JCI-2009-05824
Identificación de factores de virulencia de patogenos bacter...
101K€
Cerrado
SAF2013-45232-R
VACUNAS FRENTE A ENFERMEDADES HUMANAS PREVALENTES Y OPTIMIZA...
593K€
Cerrado
MCF_IIF Blohmke 2012
Identification of novel correlates of protection to accelera...
222K€
Cerrado
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Defining the genetic basis of differential susceptibility to infectious diseases is of importance for understanding the evolution of human genetic diversity, for identifying critical molecular pathways in disease resistance, and for the design of novel intervention strategies such as more effective vaccines.
I propose to sequence the entire coding regions of all human genes in large numbers of cases of severe tuberculosis and fatal bacterial sepsis to identify variants that have a large impact on risk of developing severe tuberculosis or dying from sepsis. I shall then apply this exome sequencing approach to define the genetic basis of variable immune responsiveness in West Africans to hepatitis B vaccine, and to a new promising T cell-inducing vaccine, developed in my group, that targets the liver-stage of malaria.
This programme will benefit from unique collections of 10,000 disease cases and in-house expertise in vaccine design, bioinformatics and statistical genetics, and will take genetic investigation of common infectious disease to near the ultimate level of analysis by using large-scale next generation sequencing.